MedPath

Research for elucidating the resistance mechanism to RET tyrosine kinase inhibitors in patients with non-small-cell lung cancer harboring with RET fusion gene

Not Applicable
Recruiting
Conditions
Advanced non-small-cell lung cancer harboring with RET fusion gene
Registration Number
JPRN-UMIN000021802
Lead Sponsor
Cancer Research Institute, Kanazawa University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

1. Having previously received alectinib 2.Patients whom an investigator deems ineligible for participation in this study for some other reason.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To find out the resistance mechanism to RET-TKI alectinib in NSCLC harboring with RET fusion gene
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath